Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7824.016 | 0.2885 | -0.0307 | 1.7164 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7824.016 | 0.8217 | 0.7838 | 1.7164 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 7825.016 | 0.9623 | 0.9542 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.00213 | uM | 7825.016 | 0.9114 | 0.8913 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 7825.016 | 0.9553 | 0.9457 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 7825.016 | 1.0004 | 1.0005 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 7825.016 | 0.9295 | 0.9138 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 7825.016 | 0.9168 | 0.8981 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 7825.016 | 0.8500 | 0.8135 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7825.016 | 0.6788 | 0.5837 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7825.016 | 0.8450 | 0.8070 | 1.6601 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 7827.016 | 0.8088 | 0.7354 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.00213 | uM | 7827.016 | 0.8979 | 0.8609 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 7827.016 | 0.9021 | 0.8669 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 7827.016 | 0.9059 | 0.8721 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 7827.016 | 0.8699 | 0.8220 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 7827.016 | 0.8464 | 0.7890 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 7827.016 | 0.7956 | 0.7164 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7827.016 | 0.7903 | 0.7087 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7827.016 | 0.7851 | 0.7012 | 1.4950 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 9347.132 | 1.0278 | 1.0376 | 1.4716 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.00213 | uM | 9347.132 | 1.0103 | 1.0140 | 1.4716 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 9347.132 | 0.7412 | 0.6318 | 1.4716 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 9347.132 | 1.0291 | 1.0394 | 1.4716 | ||
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 9347.132 | 1.0265 | 1.0359 | 1.4716 |